AstraZeneca has made a significant $2 billion equity investment in Summit Therapeutics, aiming to advance cancer treatment options through a clinical collaboration that explores next-generation drug combinations. CEO Pascal Soriot highlighted Summit’s lead drug, ivonescimab, as a groundbreaking bispecific antibody that simultaneously targets PD-1 and VEGF pathways. This dual-action approach boosts the immune system's attack on cancer cells while cutting off the tumor’s blood supply, positioning it as a potential successor to first-generation PD-1 inhibitors like Merck’s Keytruda.

Ivonescimab has already demonstrated superior performance compared to Keytruda in head-to-head trials involving patients with advanced non-small cell lung cancer, stirring considerable interest in the oncology field and fueling a multibillion-dollar rush towards similar therapies. Soriot emphasized the exciting prospect of combining ivonescimab with AstraZeneca’s antibody-drug conjugates, which could improve treatment efficacy across various tumor types that currently see limited benefits from existing PD-1 drugs. AstraZeneca’s investment grants a roughly 12% stake in Summit while allowing Summit to retain full commercial rights to ivonescimab.

Coinciding with this collaboration, AstraZeneca opened a new research and development center in Kendall Square, Cambridge, Massachusetts, valued at over $1 billion. The 570,000 square-foot facility is designed to accelerate the development of innovative treatments across multiple therapeutic areas, including cancer, obesity, COPD, and rare diseases. The facility integrates advanced robotics, continuous automation, and agentic AI to enhance the research process’s speed and productivity, ultimately aiming to deliver more effective medicines to patients faster and at lower costs.

Soriot underlined that about 20% of the new site’s investment is dedicated to robotics and AI, reflecting AstraZeneca’s commitment to harnessing cutting-edge technology in drug discovery. He described the company’s efforts as a race against disease, addressing the urgent unmet medical needs through innovative scientific approaches. This collaboration with Summit and the new R&D facility together position AstraZeneca to lead in developing transformative cancer therapies and maintain growth well beyond 2030.